New sickle cell drug candidate enters first human tests
NCT ID NCT04255875
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called PF-07209326 in 52 people, first in healthy volunteers and then in patients with sickle cell disease. The main goal was to check safety and how the body processes the drug. Researchers also looked for any early signs that the drug might help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07209326
What this could lead to
If this drug proves safe and shows early signs of working, it could point toward a new treatment option for sickle cell disease.
What could go wrong
This is a very early Phase 1 trial with only 52 participants, focused mainly on safety. It is too small and early to know if the drug will actually help patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CUIMC Research Pharmacy
New York, New York, 10032, United States
-
CUMC Research Pharmacy
New York, New York, 10032, United States
-
Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center
Atlanta, Georgia, 30322, United States
-
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York, 10032, United States
-
Foundation for Sickle Cell Disease Research
Hollywood, Florida, 33023, United States
-
Foundation for Sickle Cell Disease Research
Hollywood, Florida, 33024, United States
-
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida, 33908, United States
-
Howard University College of Medicine
Washington D.C., District of Columbia, 20060, United States
-
Lee Health - Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida, 33908, United States
-
Memorial Hermann clinical research unit
Houston, Texas, 77030, United States
-
New Haven Clinical Research Unit
New Haven, Connecticut, 06511, United States
-
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, 55114, United States
-
UT Physicians Comprehensive Sickle Cell Center Houston
Houston, Texas, 77004, United States
-
UT Physicians Comprehensive Sickle Cell Center Houston
Houston, Texas, 77030, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
-
University of Illinois at Chicago Clinical Research Center
Chicago, Illinois, 60612, United States